EXACT Therapeutics' Phase 2 trial in pancreatic cancer patients to be presented
at the 2025 AACR Special Conference on the Advances in Pancreatic Cancer
Research
Oslo, Norway, 18 September 2025. EXACT Therapeutics (Euronext Growth: EXTX), a
clinical-stage precision medicine company, is pleased to announce that a poster
on the ongoing Phase 2 ENACT trial in locally advanced pancreatic cancer
patients (NCT06850623) will be presented at the upcoming 2025 AACR Special
Conference on the Advances in Pancreatic Cancer Research-Emerging Science
Driving Transformative Solutions, which takes place during 28 September - 1
October, 2025, in Boston, Massachusetts.
The poster will be presented on the 29 September.
o Title: A phase 2 study to investigate the efficacy and safety of acoustic
cluster therapy with modified FOLFIRINOX in patients with locally advanced
pancreatic cancer
o Poster #: A068
o In collaboration with HonorHealth Research Institute, Scottsdale, AZ, United
States
The poster will be made available on the Company's website.
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications, including brain diseases. EXACT Therapeutics'
shares are traded on Euronext Growth Oslo (EXTX). Further information may be
found here: www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com